Medivir (Q4 initial take): New Clinical Programmes and Solid Funding - Redeye

Redeye is optimistic after Medivir's Q4 report. The new programme in osteogenesis imperfecta holds significant potential and can initiate phase II directly. The VBX-1000 veterinary programme, licensed to a partner, is entering the proof-of-concept stage, which is a value inflexion point. We are analysing these opportunities and will likely increase our base case in our coming update.

Länk till analysen i sin helhet: https://www.redeye.se/research/1152330/medivir-q4-initial-take-new-clinical-programmes-and-solid-funding?utm_source=finwire&utm_medium=RSS